Drug Profile
CVL 354
Alternative Names: CVL-354; Kappa opiate antagonist - Cerevel therapeuticsLatest Information Update: 28 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Cerevel Therapeutics
- Class Antidepressants; Drug withdrawal therapies
- Mechanism of Action Opioid kappa receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Major depressive disorder; Opioid-related disorders
- No development reported Substance-related disorders
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Substance-related disorders in USA
- 17 Mar 2023 Cerevel Therapeutics completes phase I trial in Major depressive disorder (In volunteers, In adults) in USA (PO) (NCT05138653)
- 01 Mar 2023 Phase-I clinical trials in Opioid-related disorders in USA (PO) (NCT05547542)